08:46 AM EST, 12/18/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Thursday the US Food and Drug Administration approval of Johnson & Johnson's ( JNJ ) Rybrevant Faspro as treatment for advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer highlighted the role of the Enhanze drug delivery technology.

Rybrevant Faspro, which is co-formulated with Halozyme's Enhanze technology, reduced administration time to about five minutes from several hours compared to intravenous delivery, and demonstrated fivefold reduction in administration-related reactions, Halozyme said.

Halozyme Chief Executive Helen Torley said products formulated with Enhanze could also boost efficiencies for healthcare providers and reduce costs for the healthcare system.

Shares of Halozyme were up 1% in recent premarket activity Thursday.